Clinical germline genetic testing for melanoma

Christopher B. Hansen, Lisa M. Wadge, Katrina Lowstuter, Kenneth Boucher, Sancy Leachman

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Clinical genetic testing for mutations in CDKN2A (cyclin-dependent kinase inhibitor 2A), a melanoma susceptibility gene, is now available. The International Melanoma Genetics Consortium advocates that genetic testing for CDKN2A should be done only as part of a research protocol. Experience with genetic testing for other cancer-susceptibility genes indicates that CDKN2A testing has enormous potential for the prevention and detection of a deadly disease. However, clinicians need to understand the benefits and shortcomings of clinical CDKN2A testing so that it can be used advantageously. Here, we examine whether CDKN2A meets the recommendations of the American Society of Clinical Oncology (ASCO) for cancer-susceptibility genetic testing. Although genetic testing for hereditary melanoma should, whenever possible, occur within research protocols, it might be successfully done outside of research protocols if attention is paid to selection, education, and counselling needs of patients; valid test interpretation; and the changing of medical management in appropriate individuals.

Original languageEnglish (US)
Pages (from-to)314-319
Number of pages6
JournalLancet Oncology
Volume5
Issue number5
DOIs
StatePublished - May 1 2004
Externally publishedYes

Fingerprint

Cyclin-Dependent Kinase Inhibitor p16
Genetic Testing
Melanoma
Research
Neoplasm Genes
Counseling
Education
Mutation
Genes
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Hansen, C. B., Wadge, L. M., Lowstuter, K., Boucher, K., & Leachman, S. (2004). Clinical germline genetic testing for melanoma. Lancet Oncology, 5(5), 314-319. https://doi.org/10.1016/S1470-2045(04)01469-X

Clinical germline genetic testing for melanoma. / Hansen, Christopher B.; Wadge, Lisa M.; Lowstuter, Katrina; Boucher, Kenneth; Leachman, Sancy.

In: Lancet Oncology, Vol. 5, No. 5, 01.05.2004, p. 314-319.

Research output: Contribution to journalArticle

Hansen, CB, Wadge, LM, Lowstuter, K, Boucher, K & Leachman, S 2004, 'Clinical germline genetic testing for melanoma', Lancet Oncology, vol. 5, no. 5, pp. 314-319. https://doi.org/10.1016/S1470-2045(04)01469-X
Hansen, Christopher B. ; Wadge, Lisa M. ; Lowstuter, Katrina ; Boucher, Kenneth ; Leachman, Sancy. / Clinical germline genetic testing for melanoma. In: Lancet Oncology. 2004 ; Vol. 5, No. 5. pp. 314-319.
@article{8558a7e2e1fa47a78c8be75b7e35f8d6,
title = "Clinical germline genetic testing for melanoma",
abstract = "Clinical genetic testing for mutations in CDKN2A (cyclin-dependent kinase inhibitor 2A), a melanoma susceptibility gene, is now available. The International Melanoma Genetics Consortium advocates that genetic testing for CDKN2A should be done only as part of a research protocol. Experience with genetic testing for other cancer-susceptibility genes indicates that CDKN2A testing has enormous potential for the prevention and detection of a deadly disease. However, clinicians need to understand the benefits and shortcomings of clinical CDKN2A testing so that it can be used advantageously. Here, we examine whether CDKN2A meets the recommendations of the American Society of Clinical Oncology (ASCO) for cancer-susceptibility genetic testing. Although genetic testing for hereditary melanoma should, whenever possible, occur within research protocols, it might be successfully done outside of research protocols if attention is paid to selection, education, and counselling needs of patients; valid test interpretation; and the changing of medical management in appropriate individuals.",
author = "Hansen, {Christopher B.} and Wadge, {Lisa M.} and Katrina Lowstuter and Kenneth Boucher and Sancy Leachman",
year = "2004",
month = "5",
day = "1",
doi = "10.1016/S1470-2045(04)01469-X",
language = "English (US)",
volume = "5",
pages = "314--319",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "5",

}

TY - JOUR

T1 - Clinical germline genetic testing for melanoma

AU - Hansen, Christopher B.

AU - Wadge, Lisa M.

AU - Lowstuter, Katrina

AU - Boucher, Kenneth

AU - Leachman, Sancy

PY - 2004/5/1

Y1 - 2004/5/1

N2 - Clinical genetic testing for mutations in CDKN2A (cyclin-dependent kinase inhibitor 2A), a melanoma susceptibility gene, is now available. The International Melanoma Genetics Consortium advocates that genetic testing for CDKN2A should be done only as part of a research protocol. Experience with genetic testing for other cancer-susceptibility genes indicates that CDKN2A testing has enormous potential for the prevention and detection of a deadly disease. However, clinicians need to understand the benefits and shortcomings of clinical CDKN2A testing so that it can be used advantageously. Here, we examine whether CDKN2A meets the recommendations of the American Society of Clinical Oncology (ASCO) for cancer-susceptibility genetic testing. Although genetic testing for hereditary melanoma should, whenever possible, occur within research protocols, it might be successfully done outside of research protocols if attention is paid to selection, education, and counselling needs of patients; valid test interpretation; and the changing of medical management in appropriate individuals.

AB - Clinical genetic testing for mutations in CDKN2A (cyclin-dependent kinase inhibitor 2A), a melanoma susceptibility gene, is now available. The International Melanoma Genetics Consortium advocates that genetic testing for CDKN2A should be done only as part of a research protocol. Experience with genetic testing for other cancer-susceptibility genes indicates that CDKN2A testing has enormous potential for the prevention and detection of a deadly disease. However, clinicians need to understand the benefits and shortcomings of clinical CDKN2A testing so that it can be used advantageously. Here, we examine whether CDKN2A meets the recommendations of the American Society of Clinical Oncology (ASCO) for cancer-susceptibility genetic testing. Although genetic testing for hereditary melanoma should, whenever possible, occur within research protocols, it might be successfully done outside of research protocols if attention is paid to selection, education, and counselling needs of patients; valid test interpretation; and the changing of medical management in appropriate individuals.

UR - http://www.scopus.com/inward/record.url?scp=2142645979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2142645979&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(04)01469-X

DO - 10.1016/S1470-2045(04)01469-X

M3 - Article

VL - 5

SP - 314

EP - 319

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 5

ER -